Antisense Oligonucleotide Therapy

Antisense oligonucleotide (ASO) therapy is a targeted RNA-based therapeutic strategy relevant to Zambian students in molecular medicine and pharmacology. This topic details the design and mechanism of synthetic, single-stranded DNA molecules that are complementary to a target mRNA sequence. By binding, ASOs can modulate gene expression through RNase H-mediated degradation, splicing modulation, or translational blockade. Students will study approved ASO drugs, such as those for spinal muscular atrophy (nusinersen) and familial hypercholesterolemia (mipomersen), and their delivery challenges. This knowledge aligns with cutting-edge biomedical curricula in Zambia, preparing learners for examinations and future involvement in the development of precision medicines for genetic disorders. Understanding ASO therapy provides insight into one of the most successful clinical translations of genetic knowledge, offering hope for treating previously untreatable conditions.